New AstraZeneca breast cancer drug shows ‘meaningful improvement’ in survivability rates

By DAILY MAIL CITY & FINANCE REPORTER

Updated: 22:00 BST, 21 April 2025

AstraZeneca has revealed that one of its new drugs has shown a ‘meaningful improvement’ in survivability rates in patients suffering from an aggressive form of breast cancer.

The FTSE 100 pharma giant said a late-stage trial of its Enhertu treatment showed the drug demonstrated a ‘highly statistically significant’ improvement on an existing drug cocktail when it was combined with another medicine, Pertuzumab. 

The trial was testing Enhertu’s effectiveness against HER2-positive metastatic breast cancer.

Only 30 per cent of those diagnosed with the illness survive beyond five years.

AstraZeneca said the results from the trial were the first in more than a decade to show a new medicine had been more effective across a broad range of patients at treating the illness, against the current standard of care.

Breakthrough: Astrazeneca said a trial of its Enhertu treatment showed the drug demonstrated a ‘highly statistically significant’ improvement on an existing treatment.

DIY INVESTING PLATFORMS

AJ Bell

AJ Bell

Easy investing and ready-made portfolios

Hargreaves Lansdown

Hargreaves Lansdown

Free fund dealing and investment ideas

interactive investor

interactive investor

Flat-fee investing from £4.99 per month

Saxo

Saxo

Get £200 back in trading fees

Trading 212

Trading 212

Free dealing and no account fee

Affiliate links: If you take out a product This is Money may earn a commission. These deals are chosen by our editorial team, as we think they are worth highlighting. This does not affect our editorial independence.

Compare the best investing account for you

:
New AstraZeneca breast cancer drug shows ‘meaningful improvement’ in survivability rates

***
Read more at DailyMail.co.uk